| Biomarker ID | 376 |
| PMID | 18767043 |
| Year | 2008 |
| Biomarker | Her-2/neu |
| Biomarker Basis | Expression Based |
| Biomolecule | Protein |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Negative Staining in Patients with Metastatic Free Survival |
| Odds Ratio/Hazard Ratio/Relative Risk | Univariate: HR = 3.41 (95% CI: 1.54-7.55); Multivariate: HR = 3.57 (95% CI: 1.68-7.59) |
| Effect on Pathways | Pathways Include:-Prolactin activation of MAPK signaling,Alpha-6 beta-1 and alpha-6 beta-4 integrin signaling,Non-small cell lung cancer,Adherens junction cell adhesion,ATM-dependent DNA damage response |
| Experiment | Metastatic Vs Non Metastatic Prostate cancer |
| Type of Biomarker | Prognostic |
| Cohort | 252 clinically localized PCa were taken into the study. 115 patients did not experience progression, and 137 did. 60 had metastasis, 192 did not. 36 patients had PCA related deaths, and 216 did not. |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p=0.002 |
| Method Used | Immunohistochemistry |
| Clinical | No |
| Remarks | Her-2/neu negative if there was staining in <5% of the marked tumor area, as focal Her-2/neu staining if 5–30% of the marked tumor area showed staining, and diffuse Her-2/neu staining if >30% of the marked tumor area showed staining. |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | ERBB2 |